CardioComm Solutions, Inc.
TSX VENTURE : EKG

CardioComm Solutions, Inc.

March 05, 2008 06:00 ET

CardioComm Solutions Sells Multiple Systems to Canadian Heart Research Centre

VICTORIA, BRITISH COLUMBIA--(Marketwire - March 5, 2008) - CardioComm Solutions, Inc. (TSX VENTURE:EKG) ("CardioComm" or the "Company") is pleased to announce that it has sold and delivered 10 WebEKG systems to the Canadian Heart Research Centre for the purposes of conducting one of the largest Phase III studies in Canada in the area of stroke prevention in patients with irregular heart beat called atrial fibrillation.

Dr. Shaun Goodman, a cardiologist and a co-chair of the Canadian Heart Research Centre and a Principal Investigator of the study in Canada remarked "CardioComm's WebEKG allows us to perform a 12 lead ECG in any physician's office and because the information is uploaded to the web site, we can see it right away from anywhere and decide if the patient has the heart rhythm disturbance suitable for study entry. We are pleased with how the WebEKG system is performing in the hands of our research assistants and in the physician offices participating in the study".

Changes to the Board of Directors

The Company also announces that Mr. Brad Harlow will be stepping down as a Chairman of the Board, effective immediately. Mr. Harlow will be replaced by Dr. Anatoly Langer. Upon his resignation, Mr. Harlow said, "I am delighted that Dr. Langer has agreed to become Chairman. His insight and knowledge of cardiovascular care in North America will guide the company during this important period as we aggressively ramp up marketing and sales of WebEKG, our new and innovative software system." In response Dr. Langer was quoted as saying "We are indebted to Mr. Harlow for his guidance of CardioComm over the past few years. He was instrumental in recognizing early the direction upon which the Company has embarked. I look forward to ongoing collaborations with him".

About CardioComm Solutions, Inc.

CardioComm's patented and proprietary technology (GlobalCardio™) is used in products for the recording, viewing, analyzing and storing of electrocardiograms (EKGs), for diagnosis and management of cardiac patients. The Company's products are sold worldwide through a combination of its external distribution network and its North American based sales team.

CardioComm has achieved its technical goals of improved access and communication through the development of a real-time EKG viewer. CardioComm is the first company to provide a real-time means of viewing EKGs over a network (LAN, WAN or Internet). This tool enables EKGs to be viewed and controlled live, by physicians, over a global virtual healthcare network. This technology is marketed as WebEKG and Global EKG Management System (GEMS™) and GlobalCardio™. CardioComm's software products have been cleared for sale in the United States by the U.S. Food and Drug Administration. The Company has earned the latest ISO 13485 certification.

On behalf of the Board of Directors of CardioComm Solutions, Inc.

Stephen R. Martin, President & CEO

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

Contact Information